MDS Pharma Services’ protocol scientists are familiar with the regulations from the FDA,
Health Canada, EMEA and other regulatory agencies. Our protocol scientists
work closely with the local institutional review boards and ethics committees that serve our phase I clinics,
to facilitate protocol approval. Additionally, the protocol scientists actively solicit
input from our pharmacokinetic/pharmacodynamic, statistical, and clinic staff, to ensure a
successful clinical study.

We can provide you with a protocol for a bioequivalence study for rapid
study start-up. We also have experience developing protocols for other clinical pharmacology studies.
We can evaluate alternative study designs, perform sample size calculations, make recommendations on
randomization and blinding, advise on PK/PD parameter selection, and aid in the selection of
appropriate sampling times.